Poor response to platinum-based chemotherapy is associated with KRAS mutation and concomitant low expression of BRAC1 and TYMS in NSCLC

Conclusions
KRAS mutation status and BRCA1 tumour expression are potential biomarkers for tailoring chemotherapy and predicting clinical outcome.

Source: Journal of International Medical Research - February 17, 2016 Category: Research Authors: Zhou, H., Dai, Y., Zhu, L., Wang, C., Fei, X., Pan, Q., Chen, J., Shi, X., Yang, Y., Tao, X., Shi, P. Tags: Research Reports Source Type: research